We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
By Adriano Marchese
GlaxoSmithKline PLC said Friday that the European Commission has granted conditional marketing authorization for Jemperli, a treatment for endometrial cancer.
The British pharmaceutical giant said the approval makes Jemperli, also known as dostarlimab, the first anti-PD-1 therapy available for endometrial cancer in Europe.
The drug is a treatment for patients with mismatch repair deficient recurrent or advanced endometrial cancer.
"Today's approval of dostarlimab means that for the first time in Europe, these women will have access to a new, innovative and much-needed therapy," Hal Barron, chief scientific officer and president of research and development, said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 23, 2021 10:30 ET (14:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions